IMMUNOBIOLOGY OF LAK CELLS
LAK 细胞的免疫生物学
基本信息
- 批准号:3186453
- 负责人:
- 金额:$ 26.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1990
- 资助国家:美国
- 起止时间:1990-02-01 至 1995-01-31
- 项目状态:已结题
- 来源:
- 关键词:CD antigens adult respiratory distress syndrome antiserum biological response modifiers biopsy carcinoma cell mediated lymphocytolysis test cis platinum compound complement cytokine cytolysis endotoxins gel electrophoresis human subject human therapy evaluation immunosuppression immunotoxicity interferons interleukin 2 interleukin 4 kidney neoplasms killer cells laboratory mouse laboratory rabbit leukocyte activation /transformation liver function lymphokines melanoma monoclonal antibody monocyte natural killer cells neoplasm /cancer classification /staging neoplasm /cancer immunology neoplasm /cancer immunotherapy passive immunization peripheral blood vessel radioimmunoassay radiotracer stress proteins tumor necrosis factor alpha vascular endothelium permeability western blottings
项目摘要
The administration of IL-2 leads to lymphocyte activation in vivo as well
as the release of several secondary cytokines resulting in tumor regression
in approximately one-third of patients with either renal cell carcinoma or
malignant melanoma. This form of immunotherapy is associated with severe
side effects, some of which are presumably mediated by tumor necrosis
factor, IL-1, and other pyrogenic cytokines generated in response to IL-2.
Indeed, the infusion of these cytokines is known to induce fever,
hypotension, and an acute respiratory distress syndrome (ARDS) in recipient
animals, all of which strongly resemble the hemodynamic and metabolic
alterations observed in cancer patients treated with IL-2. In addition,
several lines of evidence suggest that the endothelium may be directly
injured by IL-2-activated CD16+ lymphocytes (NK cells), resulting in a
diffuse increase in vascular permeability (capillary leak syndrome).
Finally, high levels of activated complement components, some of which are
known to function as potent anaphylatoxins, have been detected in the
plasma of patients undergoing immunotherapy with IL-2. This renewal grant
application will systematically evaluate leukocyte-endothelial interactions
as they relate to endothelial injury and the induction of capillary leak.
The mechanism by which complement is activated in patients undergoing
immunotherapy with IL-2 will be explored in depth. The proposal contains
several studies focused on the evaluation of agents known to antagonize the
activation of neutrophils by TNF, one of the cytokines present in the serum
of patients receiving IL-2. Other studies will evaluate agents that
inhibit the release of TNF and other cytokines capable of causing capillary
leak in experimental animals. Since the capillary leak syndrome has also
been observed in patients receiving TNF alpha and in those undergoing
treatment with high-dose GM-CSF, this investigation will provide
information relevant to the clinical use of biological response modifiers
in addition to IL-2. These proposed studies will not only clarify the
mechanism of increased vascular permeability associated with IL-2 therapy,
but will address several fundamental aspects of leukocyte-endothelial cell
interactions, lymphokine networks, and complement activation, which may be
relevant to cytokine-induced tumor regression as well as toxicity.
IL-2的施用也导致体内淋巴细胞活化
由于释放几种次级细胞因子导致肿瘤消退,
在大约三分之一的肾细胞癌患者中,
恶性黑素瘤 这种形式的免疫疗法与严重的
副作用,其中一些可能由肿瘤坏死介导
因子、IL-1和响应于IL-2产生的其他致热细胞因子。
事实上,已知这些细胞因子的输注会引起发热,
低血压和急性呼吸窘迫综合征(ARDS
动物,所有这些都非常类似于血液动力学和代谢
在用IL-2治疗的癌症患者中观察到的改变。 此外,本发明还提供了一种方法,
一些证据表明,内皮细胞可能直接
IL-2激活的CD 16+淋巴细胞(NK细胞)损伤,导致
血管通透性弥漫性增加(毛细血管渗漏综合征)。
最后,高水平的活化补体成分,其中一些是
已知作为强效过敏毒素发挥作用,
用IL-2进行免疫治疗的患者的血浆。 这份续约补助金
应用程序将系统地评价白细胞-内皮细胞相互作用
因为它们与内皮损伤和毛细血管渗漏的诱导有关。
补体在经历过以下过程的患者中被激活的机制
IL-2的免疫治疗将被深入研究。 该提案包括
几项研究集中于评价已知拮抗
TNF(血清中存在的细胞因子之一)激活中性粒细胞
接受IL-2治疗的患者。 其他研究将评估
抑制肿瘤坏死因子和其他细胞因子的释放,
在实验动物中泄漏。 由于毛细血管渗漏综合征也
在接受TNF α治疗的患者和接受
高剂量GM-CSF治疗,这项研究将提供
与生物反应调节剂临床使用相关的信息
除了IL-2。 这些拟议的研究不仅将澄清
与IL-2治疗相关的血管通透性增加的机制,
但将阐述白细胞-内皮细胞的几个基本方面,
相互作用,淋巴因子网络和补体激活,这可能是
与马槟榔碱诱导的肿瘤消退以及毒性有关。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JAMES W MIER其他文献
JAMES W MIER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JAMES W MIER', 18)}}的其他基金
Targeting Raf in Melanoma: Mechanisms for Effect & Resistance & Opportunities for
靶向 Raf 治疗黑色素瘤:作用机制
- 批准号:
7464270 - 财政年份:2008
- 资助金额:
$ 26.5万 - 项目类别:
PHASE I CLINICAL TRIAL OF DECITABINE PRIOR TO DACARBAZINE IN ADVANCED MELANOMA
达卡巴嗪治疗晚期黑色素瘤中地西他滨的 I 期临床试验
- 批准号:
7205190 - 财政年份:2005
- 资助金额:
$ 26.5万 - 项目类别:
IN VIVO EFFECTS OF IL 2--ROLE OF TNF AND TNF R FAMILIES
IL 2 的体内作用——TNF 和 TNF R 家族的作用
- 批准号:
2683717 - 财政年份:1997
- 资助金额:
$ 26.5万 - 项目类别:
IN VIVO EFFECTS OF IL 2--ROLE OF TNF AND TNF R FAMILIES
IL 2 的体内作用——TNF 和 TNF R 家族的作用
- 批准号:
2895972 - 财政年份:1997
- 资助金额:
$ 26.5万 - 项目类别:
IN VIVO EFFECTS OF IL 2--ROLE OF TNF AND TNF R FAMILIES
IL 2 的体内作用——TNF 和 TNF R 家族的作用
- 批准号:
2646453 - 财政年份:1997
- 资助金额:
$ 26.5万 - 项目类别:
相似海外基金
CLINICAL MODELS OF THE ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征的临床模型
- 批准号:
6564818 - 财政年份:2001
- 资助金额:
$ 26.5万 - 项目类别:
ADHESION MOLECULES IN ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征中的粘附分子
- 批准号:
6410976 - 财政年份:2000
- 资助金额:
$ 26.5万 - 项目类别:
CLINICAL MODELS OF THE ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征的临床模型
- 批准号:
6418789 - 财政年份:2000
- 资助金额:
$ 26.5万 - 项目类别:
CLINICAL MODELS OF THE ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征的临床模型
- 批准号:
6302122 - 财政年份:1999
- 资助金额:
$ 26.5万 - 项目类别:
ADHESION MOLECULES IN ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征中的粘附分子
- 批准号:
6309780 - 财政年份:1999
- 资助金额:
$ 26.5万 - 项目类别:
CLINICAL MODELS OF THE ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征的临床模型
- 批准号:
6109540 - 财政年份:1998
- 资助金额:
$ 26.5万 - 项目类别:
ADHESION MOLECULES IN ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征中的粘附分子
- 批准号:
6265845 - 财政年份:1998
- 资助金额:
$ 26.5万 - 项目类别: